In response to Marty Makary warning the US may lose the early‑stage drug development lead to China, Brian Scanlan says speed, AI‑driven CDMOs, and focused specialization are now critical.
Brian Scanlan
Advertisement
Managing Partner
Freedom Bioscience Partners
Partner - Life Sciences
Edgewater Capital Partners
Articles by Brian Scanlan
Advertisement
Latest Updated Articles
Advertisement
Advertisement